The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
Open accessAbstract
Background: Immunotherapy represents the future of clinical cancer treatment. The type of cancer cell death determines the antitumor immune response and thereby contributes to the efficacy of anticancer therapy and long-term survival of patients. Induction of immunogenic apoptosis or necroptosis in cancer cells does activate antitumor immunity, but resistance to these cell death modalities is common. Therefore, it is of great importance to find other ways to kill tumor cells. Recently, ferroptosis has been identified as a novel, iron-dependent form of regulated cell death but whether ferroptotic cancer cells are immunogenic is unknown. Methods: Ferroptotic cell death in murine fibrosarcoma MCA205 or glioma GL261 cells was induced by RAS-selective lethal 3 and ferroptosis was analyzed by flow cytometry, atomic force and confocal microscopy. ATP and high-mobility group box 1 (HMGB1) release were detected by luminescence and ELISA assays, respectively. Immunogenicity in vitro was analyzed by coculturing of ferroptotic cancer cells with bone-marrow derived dendritic cells (BMDCs) and rate of phagocytosis and activation/maturation of BMDCs (CD11c+CD86+, CD11c+CD40+, CD11c+MHCII+, IL-6, RNAseq analysis). The tumor prophylactic vaccination model in immune-competent and immune compromised (Rag-2−/−) mice was used to analyze ferroptosis immunogenicity. Results: Ferroptosis can be induced in cancer cells by inhibition of glutathione peroxidase 4, as evidenced by confocal and atomic force microscopy and inhibitors’ analysis. We demonstrate for the first time that ferroptosis is immunogenic in vitro and in vivo. Early, but not late, ferroptotic cells promote the phenotypic maturation of BMDCs and elicit a vaccination-like effect in immune-competent mice but not in Rag-2−/− mice, suggesting that the mechanism of immunogenicity is very tightly regulated by the adaptive immune system and is time dependent. Also, ATP and HMGB1, the best-characterized damage-associated molecular patterns involved in immunogenic cell death, have proven to be passively released along the timeline of ferroptosis and act as immunogenic signal associated with the immunogenicity of early ferroptotic cancer cells. Conclusions: These results pave the way for the development of new therapeutic strategies for cancers based on induction of ferroptosis, and thus broadens the current concept of immunogenic cell death and opens the door for the development of new strategies in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Ferroptosis: past, present and future
Li, J., Cao, F., Yin, H.-L., Huang, Z.-J., Lin, Z.-T., Mao, N., Sun, B., & Wang, G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2298-2 · Cited by 4,171
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Self-citationImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis
Kagan, V. E., Mao, G., Qu, F., Angeli, J. P. F., Doll, S., Croix, C. S., Dar, H. H., Liu, B., Tyurin, V. A., Ritov, V. B., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2238 · Cited by 3,029
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
No evidence that carotenoid pigments boost either immune or antioxidant defenses in a songbird
Koch, R. E., Kavazis, A. N., Hasselquist, D., Hood, W. R., Zhang, Y., Toomey, M. B., & Hill, G. E. (2018) · Nature Communications · doi:10.1038/s41467-018-02974-x · Cited by 1,924
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Necroptosis: The Release of Damage-Associated Molecular Patterns and Its Physiological Relevance
Kaczmarek, A., Vandenabeele, P., & Krysko, D. V. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.003 · Cited by 1,411
Self-citationAutophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
Friedmann Angeli, J. P., Krysko, D. V., & Conrad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0149-1 · Cited by 1,259
Self-citationApoptotic cell clearance: basic biology and therapeutic potential
Poon, I. K. H., Lucas, C. D., Rossi, A. G., & Ravichandran, K. S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3607 · Cited by 1,223
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
The role of necroptosis in cancer biology and therapy
Gong, Y., Fan, Z., Luo, G., Yang, C., Huang, Q., Fan, K., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1029-8 · Cited by 1,040
Necroptosis in development, inflammation and disease
Weinlich, R., Oberst, A., Beere, H. M., & Green, D. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.149 · Cited by 1,016
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Self-citationMechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800 · cited 1×
“11 14–16 18 The discovery of other forms of regulated cell death paved the way for the development of alternative strategies for cell death induction.”
Self-citationImmunogenic cell death in cancer therapy: Present and emerging inducers
Zhou, J., Wang, G., Chen, Y., Wang, H., Hua, Y., & Cai, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14356 · Cited by 719
ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences
Gong, Y.-N., Guy, C., Olauson, H., Becker, J. U., Yang, M., Fitzgerald, P., Linkermann, A., & Green, D. R. (2017) · Cell · doi:10.1016/j.cell.2017.03.020 · Cited by 689
Apoptosis and necrosis: Detection, discrimination and phagocytosis
Krysko, D. V., Vanden Berghe, T., D’Herde, K., & Vandenabeele, P. (2008) · Methods · doi:10.1016/j.ymeth.2007.12.001 · Cited by 685
Self-citationEmerging role of damage-associated molecular patterns derived from mitochondria in inflammation
Krysko, D. V., Agostinis, P., Krysko, O., Garg, A. D., Bachert, C., Lambrecht, B. N., & Vandenabeele, P. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.01.005 · Cited by 680
Self-citationThe release and activity of HMGB1 in ferroptosis
Wen, Q., Liu, J., Kang, R., Zhou, B., & Tang, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.090 · Cited by 672
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
Hassannia, B., Wiernicki, B., Ingold, I., Qu, F., Van Herck, S., Tyurina, Y. Y., Bayır, H., Abhari, B. A., Angeli, J. P. F., Choi, S. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99032 · Cited by 627
Self-citationRIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8 + T cells
Yatim, N., Jusforgues-Saklani, H., Orozco, S., Schulz, O., Barreira da Silva, R., Reis e Sousa, C., Green, D. R., Oberst, A., & Albert, M. L. (2015) · Science · doi:10.1126/science.aad0395 · Cited by 622
Molecular mechanisms of ATP secretion during immunogenic cell death
Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Métivier, D., Galluzzi, L., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.75 · Cited by 563
Hoffmann, P. R., deCathelineau, A. M., Ogden, C. A., Leverrier, Y., Bratton, D. L., Daleke, D. L., Ridley, A. J., Fadok, V. A., & Henson, P. M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200108080 · Cited by 541
Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474
Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity
Aaes, T. L., Kaczmarek, A., Delvaeye, T., De Craene, B., De Koker, S., Heyndrickx, L., Delrue, I., Taminau, J., Wiernicki, B., De Groote, P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.037 · Cited by 443
Self-citationMolecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
Self-citationSnyder, A. G., Hubbard, N. W., Messmer, M. N., Kofman, S. B., Hagan, C. E., Orozco, S. L., Chiang, K., Daniels, B. P., Baker, D., & Oberst, A. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw2004 · Cited by 374
The Dynamics of Apoptotic Cell Clearance
Elliott, M. R., & Ravichandran, K. S. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.06.029 · Cited by 319
Clearance of apoptotic and necrotic cells and its immunological consequences
Krysko, D. V., D’Herde, K., & Vandenabeele, P. (2006) · Apoptosis · doi:10.1007/s10495-006-9527-8 · Cited by 316 · cited 1×
“The levels of HMGB1 in the supernatant from the early ferroptotic cells were not statistically different from the level in viable cancer cells (figure 5C).”
Self-citationMolecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Many faces of DAMPs in cancer therapy
Krysko, O., Løve Aaes, T., Bachert, C., Vandenabeele, P., & Krysko, D. V. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.156 · Cited by 296
Self-citationImmunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine
Turubanova, V. D., Balalaeva, I. V., Mishchenko, T. A., Catanzaro, E., Alzeibak, R., Peskova, N. N., Efimova, I., Bachert, C., Mitroshina, E. V., Krysko, O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0826-3 · Cited by 281
Self-citationDefective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Kagan, V. E., Gleiss, B., Tyurina, Y. Y., Tyurin, V. A., Elenström-Magnusson, C., Liu, S.-X., Serinkan, F. B., Arroyo, A., Chandra, J., Orrenius, S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.487 · Cited by 257
Brouckaert, G., Kalai, M., Krysko, D. V., Saelens, X., Vercammen, D., Ndlovu, `., Haegeman, G., D'Herde, K., & Vandenabeele, P. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-09-0668 · Cited by 209
Self-citationWei, X., Yi, X., Lv, H., Sui, X., Lu, P., Li, L., An, Y., Yang, Y., Yi, H., & Chen, G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02857-4 · Cited by 204
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo
Scheffer, S. R., Nave, H., Korangy, F., Schlote, K., Pabst, R., Jaffee, E. M., Manns, M. P., & Greten, T. F. (2003) · International Journal of Cancer · doi:10.1002/ijc.10777 · Cited by 201
Flipping the dogma – phosphatidylserine in non-apoptotic cell death
Shlomovitz, I., Speir, M., & Gerlic, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0437-0 · Cited by 189
Goldszmid, R. S., Idoyaga, J., Bravo, A. I., Steinman, R., Mordoh, J., & Wainstok, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5940 · Cited by 187
Necroptotic cell death in anti‐cancer therapy
Krysko, O., Aaes, T. L., Kagan, V. E., D'Herde, K., Bachert, C., Leybaert, L., Vandenabeele, P., & Krysko, D. V. (2017) · Immunological Reviews · doi:10.1111/imr.12583 · Cited by 173
Self-citationFrohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0484-x · Cited by 171
PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
Wang, Y., Hao, F., Nan, Y., Qu, L., Na, W., Jia, C., & Chen, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27854 · Cited by 168
Klöditz, K., & Fadeel, B. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0146-x · Cited by 161
The oncolytic peptide LTX-315 triggers immunogenic cell death
Zhou, H., Forveille, S., Sauvat, A., Yamazaki, T., Senovilla, L., Ma, Y., Liu, P., Yang, H., Bezu, L., Müller, K., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.47 · Cited by 157
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
Sukkurwala, A. Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E. E., Galluzzi, L., Zitvogel, L., Kepp, O., et al. (2014) · OncoImmunology · doi:10.4161/onci.28473 · Cited by 151
D'Herde, K. G. M. A., & Krysko, D. V. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2261 · Cited by 145
Self-citationPanzarini, E., Inguscio, V., Fimia, G. M., & Dini, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105778 · Cited by 132
Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress
Wang, Y., Chen, Q., Shi, C., Jiao, F., & Gong, Z. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10660 · Cited by 132
Huang, C.-Y., Kuo, W.-T., Huang, Y.-C., Lee, T., & Yu, L. C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.149 · Cited by 127
Immunogenic Apoptotic Cell Death and Anticancer Immunity
Vandenabeele, P., Vandecasteele, K., Bachert, C., Krysko, O., & Krysko, D. V. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_6 · Cited by 109
Self-citationKrysko, O., Ridder, L. D., & Cornelissen, M. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000031452.75162.75 · Cited by 108
Self-citationEfficient T Cell Activation via a Toll-Interleukin 1 Receptor-Independent Pathway
Janssen, E. M., Tabeta, K., Barnes, M. J., Rutschmann, S., McBride, S. W., Bahjat, K. S., Schoenberger, S. P., Theofilopoulos, A. N., Beutler, B., & Hoebe, K. H. N. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.024 · Cited by 103
Necroptosis: A Novel Cell Death Modality and Its Potential Relevance for Critical Care Medicine
Moreno‐González, G., Vandenabeele, P., & Krysko, D. V. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2106ci · Cited by 93
Self-citationMacrophages regulate the clearance of living cells by calreticulin
Krysko, D. V., Ravichandran, K. S., & Vandenabeele, P. (2018) · Nature Communications · doi:10.1038/s41467-018-06807-9 · Cited by 89
Self-citationCell recovery by reversal of ferroptosis
Tang, H. M., & Tang, H. L. (2019) · Biology Open · doi:10.1242/bio.043182 · Cited by 83
Osman, R., Tacnet‐Delorme, P., Kleman, J.-P., Millet, A., & Frachet, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01034 · Cited by 71
Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells
Zhang, Y., Yang, S., Yang, Y., & Liu, T. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0247-4 · Cited by 70
A real-time fluorometric method for the simultaneous detection of cell death type and rate
Grootjans, S., Hassannia, B., Delrue, I., Goossens, V., Wiernicki, B., Dondelinger, Y., Bertrand, M. J. M., Krysko, D. V., Vuylsteke, M., Vandenabeele, P., et al. (2016) · Nature Protocols · doi:10.1038/nprot.2016.085 · Cited by 66
Self-citationKrysko, D. V., Brouckaert, G., Kalai, M., Vandenabeele, P., & D'Herde, K. G. M. A. (2003) · Journal of Morphology · doi:10.1002/jmor.10161 · Cited by 65
Self-citationConnecting lysosomes and mitochondria – a novel role for lipid metabolism in cancer cell death
Bartel, K., Pein, H., Popper, B., Schmitt, S., Janaki‐Raman, S., Schulze, A., Lengauer, F., Koeberle, A., Werz, O., Zischka, H., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0399-2 · Cited by 63
An emerging role for nanomaterials in increasing immunogenicity of cancer cell death
Mishchenko, T. A., Mitroshina, Е. V., Balalaeva, I. V., Krysko, O., Vedunova, M. V., & Krysko, D. V. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.004 · Cited by 55
Self-citationGarg, A. D., Krysko, D. V., Vandenabeele, P., & Agostinis, P. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.411 · Cited by 52
Self-citationAaes, T. L., Verschuere, H., Kaczmarek, A., Heyndrickx, L., Wiernicki, B., Delrue, I., Craene, B. D., Taminau, J., Delvaeye, T., Bertrand, M. J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900072 · Cited by 44
Self-citationClearance of dead cells: mechanisms, immune responses and implication in the development of diseases
Krysko, D. V., & Vandenabeele, P. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0524-6 · Cited by 40
Self-citationPrimary sterile necrotic cells fail to cross-prime CD8+T cells
Gamrekelashvili, J., Ormandy, L. A., Heimesaat, M. M., Kirschning, C. J., Manns, M. P., Korangy, F., & Greten, T. F. (2012) · OncoImmunology · doi:10.4161/onci.21098 · Cited by 38
A 3D Cell Death Assay to Quantitatively Determine Ferroptosis in Spheroids
Demuynck, R., Efimova, I., Lin, A. G., Declercq, H., & Krysko, D. V. (2020) · Cells · doi:10.3390/cells9030703 · Cited by 32
Self-citationModulatory role of calreticulin as chaperokine for dendritic cell-based immunotherapy
Bajor, A., Tischer, S., Figueiredo, C., Wittmann, M., Immenschuh, S., Blasczyk, R., & Eiz‐Vesper, B. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04423.x · Cited by 26
Melis, M. H. M., Simpson, K., Dovedi, S. J., Welman, A., MacFarlane, M., Dive, C., Honeychurch, J., & Illidge, T. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.8 · Cited by 25
Yuan, Y., Wang, Z., Yang, R., Qian, T., & Zhou, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.051 · Cited by 16
Cited by
Targeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance
Zhang, C., Liu, X., Jin, S., Chen, Y., & Guo, R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01530-y · Cited by 1,332
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 890
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
Ferroptosis in infection, inflammation, and immunity
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210518 · Cited by 824
Metadata
- Authors
- Efimova, I., Catanzaro, E., Van der Meeren, L., Turubanova, V. D., Hammad, H., Mishchenko, T. A., Vedunova, M. V., Fimognari, C., Bachert, C., Coppieters, F., Lefever, S., Skirtach, A. G., Krysko, O., & Krysko, D. V.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-11
- Volume
- 8
- Issue
- 2
- Pages
- e001369
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3106235644
- Cited by
- 520
- References
- 83
- FWCI
- 25.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.